Teaching case: A man with a progressive gait impairment and visual compromise
Primary progressive multiple sclerosis can present with a wide variety of symptoms. We report a case of a 52-year-old man presenting with visual symptoms and gait impairment in whom a diagnosis of a primary progressive multiple sclerosis was established. Symptomatic treatment with dalfampridine was...
- Autores:
-
Toro, Jaime
Burbano, Lisseth Estefania
Zamora, Adrián
Jones, Erica
- Tipo de recurso:
- Article of journal
- Fecha de publicación:
- 2015
- Institución:
- Universidad El Bosque
- Repositorio:
- Repositorio U. El Bosque
- Idioma:
- eng
- OAI Identifier:
- oai:repositorio.unbosque.edu.co:20.500.12495/5116
- Acceso en línea:
- http://hdl.handle.net/20.500.12495/5116
https://doi.org/10.1016/j.msard.2015.02.001
- Palabra clave:
- Dalfampridine
Gait disorders
Primary progresive multiple sclerosis
- Rights
- openAccess
- License
- Acceso abierto
id |
UNBOSQUE2_2f11c9765f44d70285c92c8f3815b302 |
---|---|
oai_identifier_str |
oai:repositorio.unbosque.edu.co:20.500.12495/5116 |
network_acronym_str |
UNBOSQUE2 |
network_name_str |
Repositorio U. El Bosque |
repository_id_str |
|
dc.title.spa.fl_str_mv |
Teaching case: A man with a progressive gait impairment and visual compromise |
dc.title.translated.spa.fl_str_mv |
Teaching case: A man with a progressive gait impairment and visual compromise |
title |
Teaching case: A man with a progressive gait impairment and visual compromise |
spellingShingle |
Teaching case: A man with a progressive gait impairment and visual compromise Dalfampridine Gait disorders Primary progresive multiple sclerosis |
title_short |
Teaching case: A man with a progressive gait impairment and visual compromise |
title_full |
Teaching case: A man with a progressive gait impairment and visual compromise |
title_fullStr |
Teaching case: A man with a progressive gait impairment and visual compromise |
title_full_unstemmed |
Teaching case: A man with a progressive gait impairment and visual compromise |
title_sort |
Teaching case: A man with a progressive gait impairment and visual compromise |
dc.creator.fl_str_mv |
Toro, Jaime Burbano, Lisseth Estefania Zamora, Adrián Jones, Erica |
dc.contributor.author.none.fl_str_mv |
Toro, Jaime Burbano, Lisseth Estefania Zamora, Adrián Jones, Erica |
dc.contributor.orcid.none.fl_str_mv |
Toro, Jaime [0000-0001-7129-0058] |
dc.subject.keywords.spa.fl_str_mv |
Dalfampridine Gait disorders Primary progresive multiple sclerosis |
topic |
Dalfampridine Gait disorders Primary progresive multiple sclerosis |
description |
Primary progressive multiple sclerosis can present with a wide variety of symptoms. We report a case of a 52-year-old man presenting with visual symptoms and gait impairment in whom a diagnosis of a primary progressive multiple sclerosis was established. Symptomatic treatment with dalfampridine was started but did not result in a considerable improvement. Gait disorders in multiple sclerosis are common and can have a considerable effect over the patient׳s quality of life. Dalfampridine is the first drug approved for the symptomatic treatment of gait in MS, although only a 40% of patients show an objective response to this medication. Primary progressive multiple sclerosis represents a therapeutic challenge. Currently, there are no disease modifying treatments approved but there are several medications undergoing assessment for this indication. Further research in the underlying pathophysiology of PPMS will help us develope more successful disease-modifying treatments. Meanwhile, a symptomatic approach should be offered in order to improve the patient׳s quality of life. |
publishDate |
2015 |
dc.date.issued.none.fl_str_mv |
2015 |
dc.date.accessioned.none.fl_str_mv |
2020-11-23T17:37:51Z |
dc.date.available.none.fl_str_mv |
2020-11-23T17:37:51Z |
dc.type.coar.fl_str_mv |
http://purl.org/coar/resource_type/c_2df8fbb1 |
dc.type.coarversion.fl_str_mv |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
dc.type.local.none.fl_str_mv |
Artículo de revista |
dc.type.coar.none.fl_str_mv |
http://purl.org/coar/resource_type/c_6501 |
dc.type.driver.none.fl_str_mv |
info:eu-repo/semantics/article |
format |
http://purl.org/coar/resource_type/c_6501 |
dc.identifier.issn.none.fl_str_mv |
2211-0356 |
dc.identifier.uri.none.fl_str_mv |
http://hdl.handle.net/20.500.12495/5116 |
dc.identifier.doi.none.fl_str_mv |
https://doi.org/10.1016/j.msard.2015.02.001 |
dc.identifier.instname.spa.fl_str_mv |
instname:Universidad El Bosque |
dc.identifier.reponame.spa.fl_str_mv |
reponame:Repositorio Institucional Universidad El Bosque |
dc.identifier.repourl.none.fl_str_mv |
repourl:https://repositorio.unbosque.edu.co |
identifier_str_mv |
2211-0356 instname:Universidad El Bosque reponame:Repositorio Institucional Universidad El Bosque repourl:https://repositorio.unbosque.edu.co |
url |
http://hdl.handle.net/20.500.12495/5116 https://doi.org/10.1016/j.msard.2015.02.001 |
dc.language.iso.none.fl_str_mv |
eng |
language |
eng |
dc.relation.ispartofseries.spa.fl_str_mv |
Multiple Sclerosis and Related Disorders, 2211-0356, Vol. 4, No. 2, 2015, p. 176-179 |
dc.relation.uri.none.fl_str_mv |
https://www.msard-journal.com/article/S2211-0348(15)00008-5/fulltext |
dc.rights.local.spa.fl_str_mv |
Acceso abierto |
dc.rights.accessrights.none.fl_str_mv |
http://purl.org/coar/access_right/c_abf2 info:eu-repo/semantics/openAccess Acceso abierto |
dc.rights.creativecommons.none.fl_str_mv |
2015-03 |
rights_invalid_str_mv |
Acceso abierto http://purl.org/coar/access_right/c_abf2 2015-03 |
eu_rights_str_mv |
openAccess |
dc.format.mimetype.none.fl_str_mv |
application/pdf |
dc.publisher.spa.fl_str_mv |
Elsevier |
dc.publisher.journal.spa.fl_str_mv |
Multiple Sclerosis and Related Disorders |
institution |
Universidad El Bosque |
bitstream.url.fl_str_mv |
https://repositorio.unbosque.edu.co/bitstreams/7410905b-6918-4fa1-a0eb-ab098760b8e6/download https://repositorio.unbosque.edu.co/bitstreams/96acf6b8-e49d-4804-afa2-c624e158368d/download https://repositorio.unbosque.edu.co/bitstreams/cf5b29e6-3ec5-460f-8ab6-2771898467c2/download https://repositorio.unbosque.edu.co/bitstreams/44ce2450-658b-40b6-b162-af70f7cef9e1/download |
bitstream.checksum.fl_str_mv |
eb1073d3c8ba79abb0422eb43d83e49f 8a4605be74aa9ea9d79846c1fba20a33 579ceed07471bd6ac8a78083e2cde029 a8f5c5a4cd5f72353123b1cb3e2bdaa7 |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 MD5 |
repository.name.fl_str_mv |
Repositorio Institucional Universidad El Bosque |
repository.mail.fl_str_mv |
bibliotecas@biteca.com |
_version_ |
1828164448992362496 |
spelling |
Toro, JaimeBurbano, Lisseth EstefaniaZamora, AdriánJones, EricaToro, Jaime [0000-0001-7129-0058]2020-11-23T17:37:51Z2020-11-23T17:37:51Z20152211-0356http://hdl.handle.net/20.500.12495/5116https://doi.org/10.1016/j.msard.2015.02.001instname:Universidad El Bosquereponame:Repositorio Institucional Universidad El Bosquerepourl:https://repositorio.unbosque.edu.coapplication/pdfengElsevierMultiple Sclerosis and Related DisordersMultiple Sclerosis and Related Disorders, 2211-0356, Vol. 4, No. 2, 2015, p. 176-179https://www.msard-journal.com/article/S2211-0348(15)00008-5/fulltextTeaching case: A man with a progressive gait impairment and visual compromiseTeaching case: A man with a progressive gait impairment and visual compromiseArtículo de revistahttp://purl.org/coar/resource_type/c_6501http://purl.org/coar/resource_type/c_2df8fbb1info:eu-repo/semantics/articlehttp://purl.org/coar/version/c_970fb48d4fbd8a85DalfampridineGait disordersPrimary progresive multiple sclerosisPrimary progressive multiple sclerosis can present with a wide variety of symptoms. We report a case of a 52-year-old man presenting with visual symptoms and gait impairment in whom a diagnosis of a primary progressive multiple sclerosis was established. Symptomatic treatment with dalfampridine was started but did not result in a considerable improvement. Gait disorders in multiple sclerosis are common and can have a considerable effect over the patient׳s quality of life. Dalfampridine is the first drug approved for the symptomatic treatment of gait in MS, although only a 40% of patients show an objective response to this medication. Primary progressive multiple sclerosis represents a therapeutic challenge. Currently, there are no disease modifying treatments approved but there are several medications undergoing assessment for this indication. Further research in the underlying pathophysiology of PPMS will help us develope more successful disease-modifying treatments. Meanwhile, a symptomatic approach should be offered in order to improve the patient׳s quality of life.Acceso abiertohttp://purl.org/coar/access_right/c_abf2info:eu-repo/semantics/openAccessAcceso abierto2015-03ORIGINALToro_Jaime_2015.pdfToro_Jaime_2015.pdfapplication/pdf614852https://repositorio.unbosque.edu.co/bitstreams/7410905b-6918-4fa1-a0eb-ab098760b8e6/downloadeb1073d3c8ba79abb0422eb43d83e49fMD51LICENSElicense.txtlicense.txttext/plain; charset=utf-81748https://repositorio.unbosque.edu.co/bitstreams/96acf6b8-e49d-4804-afa2-c624e158368d/download8a4605be74aa9ea9d79846c1fba20a33MD52THUMBNAILToro_Jaime_2015.pdf.jpgToro_Jaime_2015.pdf.jpgIM Thumbnailimage/jpeg12927https://repositorio.unbosque.edu.co/bitstreams/cf5b29e6-3ec5-460f-8ab6-2771898467c2/download579ceed07471bd6ac8a78083e2cde029MD53TEXTToro_Jaime_2015.pdf.txtToro_Jaime_2015.pdf.txtExtracted texttext/plain20007https://repositorio.unbosque.edu.co/bitstreams/44ce2450-658b-40b6-b162-af70f7cef9e1/downloada8f5c5a4cd5f72353123b1cb3e2bdaa7MD5420.500.12495/5116oai:repositorio.unbosque.edu.co:20.500.12495/51162024-02-07 01:24:09.102open.accesshttps://repositorio.unbosque.edu.coRepositorio Institucional Universidad El Bosquebibliotecas@biteca.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 |